Two Chinese Biotechs Raise $104m To Challenge GSK’s Shingrix
MAXVAX Biotechnology and Beijing Luzhu Biotechnology raise new funds to progress their recombinant herpes zoster vaccine candidates with novel adjuvants, while multiple other ventures in China complete new financings across multiple therapeutic areas and modalities.
You may also be interested in...
A preliminary analysis of Russian Phase III results for azvudine, China's first home-grown antiviral for COVID-19, shows it reached two primary endpoints, but a separate Chinese study produced mixed results.
12 biotechs in China are preparing to compete for domestic market share for their home-grown HER2-targeted antibody-drug conjugates amid Enhertu’s in-roads in the country.
Inspired by the discovery of the phytochemical corynoline being a potential MYC synthetic lethality agent, Anticancer Bioscience has designed and identified preclinical candidates that could lead to first-in-class innovative drugs.